Coherus BioSciences feels its bearing and clout in the US pegfilgrastim market will stand it in good stead as other players scrabble to compete on the more lucrative formulations of Amgen’s Neulasta.

Celltrion joins a number of other adalimumab competitors with dual pricing strategies as Humira biosimilars finally gain some traction in the US market.

Early-stage companies pioneering new modalities discussed the future of cardiometabolic therapy and partnering with big pharma at the LSX conference in London.

Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.